Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Pantarhei Bioscience BV

Home Clinical Trial Sponsors and OrganizationsPantarhei Bioscience BV

Pantarhei Bioscience BV

ACTIVE

Netherlandswww.pantarheibio.comPrivate11–50 employeesEstablished: 2001-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2001

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1

25.0%

Trial Status Distribution

Active, not recruiting

4

100.0%

Clinical Trials

Trials sponsored by this organization (4)

A dose finding study with an active control group (Yasmin) to assess the contraceptive efficacy and the efficacy on liver function of estetrol combined with 3 mg drospirenone by daily oral administration to healthy female volunteers for 3 cycles of 24 days each followed by a 4 day treatment pause. - DOC-2

Active, not recruiting

A double-blind, placebo-controlled, randomised, N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on mood in women who experience mood disturbances during oral contraception-use. - ARC-MOOD

Active, not recruiting

A double-blind, placebo-controlled, randomized, N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on sexual functioning in 6 women who experience a decrease in sexual functioning due to their oral contraception-use. - ARC-SOLO

Active, not recruiting

Jan 20086 participants

A feasibility study into the contraceptive effect of estetrol alone or combined with either progesterone or desogestel by daily oral administration to healthy female volunteers for 28 days - Ovulation inhibition of estetrol

Active, not recruiting

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations